Latest News and Press Releases

-- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate –-- Reloxaliase Well-Tolerated Over 12 Weeks of Dosing...

NEWTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...

-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on...

NEWTON, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...

NEWTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...

-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROXTM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing;...

NEWTON, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...

-- Alexey Margolin, Ph.D. to Transition to Chairman of the Board -- -- URIROX-2™ Initiated; URIROX-1™ Topline Data Expected in Second Half of 2019 -- -- Multiple Catalysts Expected Across Pipeline...

-- Primary Efficacy Endpoint of Change in Urinary Oxalate Excretion at Four Weeks -- -- URIROX-2™, Second Pivotal Phase 3 Trial, Initiated in Fourth Quarter of 2018 -- -- URIROX-1™, First Pivotal...

-- Global Phase 3 URIROX-1™ Trial Ongoing; Expect to Initiate Second Phase 3 Study, URIROX-2™, in 2018  -- -- Presented Preclinical Proof-of-Concept Data on ALLN-346 at American College of...